Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FERMT2 | Q96AC1 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7960481 | 0.88 | FERMT2 (0.56) | FERMT2GAAALDH1A1NPSR1CYP1A2 | |
| SCHEMBL11198510 | 0.82 | CDK1 (0.42) | FERMT2ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL17678178 | 0.81 | KDM4E (0.45) | FERMT2ALDH1A1CYP1A2SMN1; SMN2FLT3 | |
| SCHEMBL16803419 | 0.81 | SMN1; SMN2 (0.44) | FERMT2ALDH1A1TSHRSMN1; SMN2POLB | |
| SCHEMBL8996432 | 0.81 | FERMT2 (0.56) | FERMT2GAAALDH1A1NPSR1CYP1A2 | |
| SCHEMBL3868083 | 0.81 | FERMT2 (0.45) | FERMT2GAAALDH1A1NPSR1SMN1; SMN2 | |
| SCHEMBL10099695 | 0.78 | SMN1; SMN2 (0.43) | ALDH1A1CYP1A2TSHRSMN1; SMN2POLB | |
| SCHEMBL17761960 | 0.78 | LMNA (0.56) | ALDH1A1NPSR1CYP1A2FLT3 | |
| SCHEMBL742145 | 0.78 | PTGER4 (0.47) | ALDH1A1NPSR1CYP1A2SMN1; SMN2 | |
| SCHEMBL4800824 | 0.78 | KCNH2 (0.42) | FERMT2GAANPSR1CYP1A2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538115-B2 | Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-05-26 | — | — | US | disclosed |
| EP-1487821-B1 | BENZODIAZEPINE-SUBSTITUTED PIPERIDINES FOR UTILIZATION IN THE TREATMENT OF CARDIOVASCULAR DISEASES | BOEHRINGER INGELHEIM PHARMA (DE) | 2007-03-21 | — | — | EP | disclosed |
| US-7026312-B2 | Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-04-11 | — | — | US | disclosed |
| US-20050215546-A1 | Novel substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-09-29 | — | — | US | disclosed |
| US-20030236282-A1 | Novel substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. (DE) | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236282-A1 | Novel substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof | P2RX5, CALCRL, ADRA1D | FERMT2 2650/4885GAA 2132/4885ALDH1A1 761/4885 |
| US-20050215546-A1 | Novel substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof | P2RX3, P2RX5, P2RX2 | FERMT2 2919/4885GAA 2148/4885ALDH1A1 786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.